Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
Completed · Phase 1
Conditions studied: Type2 Diabetes Mellitus
In brief
The purpose of this study is to examine the drug exposure and drug effects on subjects with moderate hepatic impairment after a single oral dose of bexagliflozin tablets, 20mg. The study will also evaluate how safe the study drug is and how well the study drug is tolerated in subjects with moderate hepatic impairment.
Key facts
- Study ID
- NCT03557658
- Run by
- Theracos
- People needed
- 16
- Starts
- 2018-07-26
- Expected to finish
- 2018-12-26
- Last updated by the study team
- 2021-06-03
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Research Site 1 — Boston, Massachusetts, United States
- Clinical Research Site 2 — Saint Paul, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.